SWAN Isotopen
SWAN Isotopen AG operates a commercial radiopharmaceuticals production
facility on the campus of the University Hospital Bern.
Production
SWAN Isotopen AG operates a commercial radiopharmaceuticals production facility on the campus of the University Hospital Bern.
Europe
The facility is one of the most modern radiopharmaceutical production sites in Europe situated in the heart of a renowned University Hospital.
Radiopharmaceuticals
The company produces and distributes GMP radiopharmaceuticals used for molecular imaging/diagnosis.
Development
In close collaboration with the University of Bern (radiochemistry and high energy physics research groups) the company participates in the development of targeted radio therapeutics.
Oncology
SWAN Isotopen AG’s products find their application mostly in the field of oncology. They are used for tumor diagnosis and therapy monitoring and thus allow the perfect adaptation of treatments to the patients’ needs.
Transport
SWAN Isotopen AG is one of the few companies in Switzerland and the only company in the Espace Mittelland to offer a transport service for radioactive materials.News
Information for professionals – PET Tracers
Our products are manufactured according to the international GMP guidelines (Good Manufacturing Practices). They are distributed according to the international GDP guidelines (Good Distribution Practices).
These precautions guarantee your patients the highest quality products.
Flu-SWAN, a tracer for PET (positron emission tomography), is an isotonic [18F]-Fludeoxyglucose solution calibrated at 185 MBq/ml.
It is a ready-to-use radiodiagnostic for direct application.
Flu-SWAN has a physiological pH and, in addition to [18F] Fludeoxyglucose, contains only sodium chloride and 0.5% ethanol. It contains no buffer solution; the ethanol in the solution stabilizes the product with respect to a possible radiolysis. The shelf-life of the product is 12 hours after EOS (end of synthesis).
SWAN-PSMA-1007
SMC MA-no.: 67370
Production days: Monday, Wednesday and Thursday
SWAN-PSMA-1007 (18F-PSMA-1007) is a radiopharmaceutical used in positron emission tomography (PET) imaging for the detection of prostate cancer.
It specifically targets the Prostate-Specific Membrane Antigen (PSMA), which is overexpressed on the surface of prostate cancer cells. The radiotracer is labeled with the radioactive isotope fluorine-18 (18F), which emits positrons detectable by PET scanners.
Key characteristics of 18F-PSMA-1007 include:
- High Affinity for PSMA: It binds effectively to PSMA, allowing for precise imaging of prostate cancer cells.
- Fluorine-18 Labeling: The fluorine-18 isotope has a half-life of approximately 110 minutes, making it suitable for clinical imaging while providing high-resolution images.
- Low Urinary Excretion: Unlike some other PSMA-targeting agents, 18F-PSMA-1007 has relatively low urinary excretion, which helps in reducing background noise in pelvic imaging, improving the detection of prostate cancer lesions.
18F-PSMA-1007 is used primarily for:
- Initial Staging: To determine the extent of prostate cancer at the time of diagnosis.
- Restaging: To detect recurrence or metastasis in patients with rising prostate-specific antigen (PSA) levels after initial treatment.
This radiopharmaceutical helps in better visualization of prostate cancer spread, aiding in the accurate assessment and management of the disease.
SWAN-Cholin is a radiopharmaceutical for the assessment of the local tumor extent of a proven prostate carcinoma by PET (positron emission tomography). It is a radioactive 18F-labeled analog to natural choline, which is a substrate for the synthesis of cell membrane components.
SWAN-Choline is a ready-to-use radiodiagnostic for direct application.
1 ml solution for injection contains 222 MBq/ml of the active ingredient [18F] Fluoromethylcholine at the time of calibration. The included excipients are sodium chloride and water for injections. It contains no buffer solution or preservative. The shelf life of the product is 10 hours after EOS (end of synthesis).
Neuraceq is a radiodiagnostic used to visualize the density of neuritic β-amyloid plaques in the brain of adult patients with cognitive impairment who are being examined for Alzheimer’s disease (AK) or other causes of cognitive impairment.
Neuraceq should be used in conjunction with a clinical examination only.
1 ml solution for injection contains 300 MBq Florbetaben (18F) at the time of calibration indicated on the package. The shelf life of the product is 10 hours after EOS (end of synthesis).
Production according to Formula magistralis
SWAN Isotopen AG also produces radiopharmaceuticals for medical prescriptions according to Formula magistralis.
-
- Gallium-68 (Ga-68)
- Lutetium-177 (Lu-177)
